17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson's disease are associated with LRRC37A/2 expression in astrocytes.

"publicly available rna-seq expression data from human postmortem dorsolateral prefrontal (pfc) and temporal (tcx) cortices (table s5 ) and associated genotype data were obtained from synapse (synapse org; the religious orders study and memory and aging project (rosmap) syn3219045; mayornaseq syn5550404; commonmind consortium syn2759792). data were further processed using a publicly available in-house wgs qc pipeline ( https://github com/ricardovialle/wgs-qc-pipeline )."

"data were further processed using a publicly available in-house wgs qc pipeline ( https://github com/ricardovialle/wgs-qc-pipeline )."

"Declarations DeclarationsEthical Approval and Consent to ParticipateNot applicable. Consent for publicationAll authors read and approved the final manuscript Competing interestsAMG: Scientific advisory board (SAB) for Denali Therapeutics (2015–2018), SAB for Pfizer (2019), SAB for Genentech, consultant for GSK, AbbVie, Biogen and Eisai. All other authors declare no competing interests. Declarations Ethical Approval and Consent to Participate Not applicable. Competing interests AMG: Scientific advisory board (SAB) for Denali Therapeutics (2015–2018), SAB for Pfizer (2019), SAB for Genentech, consultant for GSK, AbbVie, Biogen and Eisai. All other authors declare no competing interests."

"Conceptualization: KRB, JFC, AMG. Methodology : KRB, JDC. Validation: KRB, DAP. Formal Analysis: KRB, DAP, YL, SB-C, ZG-O, PH, AS, SB, TP. Investigation : KRB, DAP, YL. Resources: AC, CMK, SJF, BHK, IP, YJP, AC, TR, JFC, AMG. Data Curation : KRB, YL, SB-C, ZG-O, PH, AS, SB, IPDGC, TP. Writing – Original Draft: KRB. Writing – Review and Editing : KRB, YL, AER, SB-C, ZG-O, CMK, IP, TP, TR, JFC, AMG. Visualization: KRB, TP. Supervision : AMG. Funding Acquisition: KRB, JFC, AMG. All authors read and approved the final manuscript. Funding This work was supported by funding from the BrightFocus Foundation (KRB), Association for Frontotemporal Degeneration (KRB) and CurePSP (KRB). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. NIH AG062683 (J.TCW), Rainwater Charitable Organization (CMK), NIH AG046374 (CMK). The McGill cohort was supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program, and Parkinson Canada. ZGO is supported by the Fonds de recherche du Québec—Santé (FRQS) Chercheurs-boursiers award given with Parkinson Quebec, and is a Parkinson Canada New Investigator awardee. The access to the McGill participants for this research has been made possible in part thanks to the Quebec Parkinson’s Network (http://rpq-qpn.ca/en/). NIH [R01AG054008, R01NS095252, R01AG060961, R01 AG060961] to JFC, the Rainwater Charitable Foundation/Tau Consortium (JFC), Genentech/Roche, and an Alexander Saint-Amand Scholarship (JFC). This work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services: project numbers 1ZIA-NS003154, Z01-AG000949-02 and Z01-ES101986. BrightFocus Foundation,Association for Frontotemporal Degeneration,CurePSP,Rainwater Charitable Foundation,National Institutes of Health,Michael J. Fox Foundation for Parkinson's Research,Canadian Consortium on Neurodegeneration in Aging,Canada First Research Excellence Fund,Fonds de Recherche du Québec—Santé"